Trial Profile
Prospective study of patients treated with pegylated interferon-alpha 2b (PegIntron) for metastasizing ileal/coecal carcinoids.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Feb 2014
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary)
- Indications Intestinal cancer; Neuroendocrine carcinoma
- Focus Therapeutic Use
- 27 Jun 2011 New trial record